The Schizophrenia Drugs Market is expected to reach US$ 10.47 billion by 2033 from US$ 7.68 billion in 2024, with a CAGR of 3.50% from 2025 to 2033. The rising incidence of schizophrenia and other ...

Some people who took a new schizophrenia drug for a year improved with only a few side effects, but many dropped out of the research, the company announced Thursday. The results underscore the ...

Treatment with glucagon-like peptide-1 receptor agonists (GLP-1s) was associated with lower risks of psychiatric ...

Schizophrenia is a complex mental health condition characterized by a disruption in a person’s thoughts, perceptions, emotions, and behavior. It can be a debilitating condition, but with proper ...

Israeli pharmaceutical giant Teva receives FDA approval for WELTRUZA, a new long-acting injection for schizophrenia that ...

People with schizophrenia who were also taking GLP-1 drugs for diabetes had fewer psychiatric relapses in a large study of US ...

For individuals diagnosed with schizophrenia, maintaining a daily medication routine can feel like an insurmountable challenge. The cognitive impairments associated with the disorder often interfere ...

Using a clock, virtual calendar, medication management app, or even a handwritten note, set a reminder to take your medication. If using a device, set the reminder to go off every day at the same time ...

GLP-1 use was also associated with fewer psychiatric emergency department visits. The association was observed mainly with ...

Many drugs are available for schizophrenia, but insufficient efficacy and intolerable side effects leave an unmet need that biotech companies are still trying to fill. LB Pharmaceuticals is not ...

The general consensus among experts is that TRS is a condition in which an individual’s symptoms haven’t responded to two or more antipsychotic medicines given at a therapeutic dose for at least six ...